Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer drug TRX-221 trial halted early – what we know

NCT ID NCT06186076

Terminated Disease control Sponsor: Therapex Co., Ltd Source: ClinicalTrials.gov ↗

First seen Apr 03, 2026 · Last updated May 08, 2026 · Updated 5 times

Summary

This study tested a new drug called TRX-221 in people with a specific type of advanced lung cancer (EGFR mutant NSCLC) that had stopped responding to standard treatments. The goal was to see if TRX-221 was safe and could shrink tumors. The trial was stopped early after enrolling 19 participants, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Chungbuk National University Hospital

    Chungju, North Chungcheong, 28644, South Korea

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, Kyeongki, 13620, South Korea

  • Severance Hospital

    Seoul, 03722, South Korea

  • The Catholic University of Korea St. Vincent Hospital

    Suwon, Kyeongki, 16247, South Korea

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER